Skip to main content

Advertisement

Table 1 Comparison of the two groups by preoperative and intraoperative characteristics

From: Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study

Factor Isolyte-M® group (n:100) Voluven® 6% group (n:100) p value*
  Mean ± SD Mean ± SD  
Age 61.81 ± 10.12 61.52 ± 9.29 0.833
BMI (kg/m2) 27.88 ± 3.96 29.02 ± 4.61 0.063
LVEF (%) 53.72 ± 10.81 52.33 ± 11.08 0.370
Cross-clamp time (min) 53.57 ± 20.12 55.58 ± 17.22 0.449
CPB time (min) 79.69 ± 27.93 82.57 ± 23.98 0.435
Graft # 3.22 ± 1.06 3.10 ± 0.90 0.390
  n:% n:% p value**
Patient Total 100 100  
Male sex 77 74 0.622
Current/Ex-smoker 67 63 0.553
Diabetes Mellitus 46 42 0.569
Hypertension 65 62 0.659
Dyslipidemia 79 76 0.611
Preoperative β-blocker use 40 47 0.318
Peripheral Arterial Diseasea 1 6 0.118***
Stroke - 1 1.000***
Carotid Diseaseb 7 5 0.552***
COPD/Asthma 14 15 0.841
  1. *independent samples t-test.
  2. **chi-square test.
  3. ***Fisher’s exact test.
  4. aHistory of therapeutic vascular intervention, history of claudication, angiography/non-invasive proven peripheral arterial disease.
  5. bHistory of carotid intervention or angiographic/non-invasive proven >40% stenosis of either carotid.
  6. BMI: body mass index, LVEF: left ventricular ejection fraction.
  7. CPB: cardiopulmonary bypass, COPD: chronic obstructive pulmonary disease.